Castle Biosciences, Inc.

NasdaqGM CSTL

Castle Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 1.95%

Castle Biosciences, Inc. Net Income Margin is 1.95% for the Trailing 12 Months (TTM) ending September 30, 2024, a 104.95% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Castle Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -39.32%, a 5.54% change year over year.
Castle Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -41.63%, a -20.82% change year over year.
Castle Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -34.46%, a -549.76% change year over year.
Castle Biosciences, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -5.30%, a -134.15% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: CSTL

Castle Biosciences, Inc.

CEO	Mr. Derek J. Maetzold
IPO Date	July 25, 2019
Location	United States
Headquarters	505 South Friendswood Drive
Employees	710
Sector	Health Care
Industries Biotechnology Clinical Trials Cosmetics Pharmaceuticals

Description

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Key trends

Past 5 years